GPRC5D-Directed Therapies for Multiple Myeloma — An Interview with Prof Rakesh Popat
Featuring an interview with Prof Rakesh Popat, including the following topics: Overview of GPRC5D and its clinical significance (0:00) Key findings from Phase II TALisman study regarding dysgeusia assessment for patients receiving talquetamab (2:30) Mitigating dysgeusia and dry mouth arising from GPRC5D-directed therapy (6:25) Key findings from the Phase III MonumenTAL-3 study (11:49) Selection factors for GPRC5D- and BCMA-directed therapies (15:16) Managing extramedullary multiple myeloma (MM) with GPRC5D-targeted therapies and beyond (18:30) Key findings with arlocabtagene autoleucel (arlo-cel) for relapsed/refractory (R/R) MM (20:47) Ramantamig and other GPRC5D-targeted approaches (25:32) Comparing arlo-cel to ciltacabtagene autoleucel for MM; CNS issues with GPRC5D-directed therapies (28:42) Case: A man in his late 70s with a history of chronic obstructive pulmonary disease and t(4;14) R/R MM who receives fourth-line talquetamab and attains a very good partial response (38:27) Cases: A man in his late 40s with t(11;14), del(17p) R/R MM who enrolls in the Phase II QUINTESSENTIAL-2 study for third-line treatment; a man in his late 60s with t(11;14), del(17p) MM and early relapse after third-line autologous stem cell transplant (45:18) Guidance on sequencing BCMA- and GPRC5D-directed therapies (47:35) Importance of tumor debulking; access to arlo-cel (52:27) CME information and select publications
